ixekizumab psoriatic arthritis
Selected indexed studies
- Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis. (Drugs Today (Barc), 2023) [PMID:36847624]
- Ixekizumab for Psoriatic Arthritis: Safety, Efficacy, and Patient Selection. (J Inflamm Res, 2021) [PMID:34949934]
- Ixekizumab in the treatment of psoriatic arthritis. (Immunotherapy, 2021) [PMID:33167745]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis. (2023) pubmed
- Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. (2017) pubmed
- Ixekizumab in the treatment of psoriatic arthritis. (2021) pubmed
- Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. (2017) pubmed
- Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. (2020) pubmed
- Vaccination recommendations for adults receiving biologics and oral therapies for psoriasis and psoriatic arthritis: Delphi consensus from the medical board of the National Psoriasis Foundation. (2024) pubmed
- Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. (2024) pubmed
- Ixekizumab for Psoriatic Arthritis: Safety, Efficacy, and Patient Selection. (2021) pubmed
- A review of ixekizumab in the treatment of psoriatic arthritis. (2018) pubmed
- A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. (2020) pubmed